Are you Dr. Villablanca?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 63 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
4650 W Sunset Blvd
Los Angeles, CA 90027Phone+1 323-669-2121Fax+1 323-660-7128
Summary
- Dr. Judith Villablanca, MD is a pediatric hematologist/oncologist in Los Angeles, California. She is currently licensed to practice medicine in California.
Education & Training
- University of MinnesotaFellowship, Pediatric Hematology/Oncology, 1986 - 1989
- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Pediatrics, 1983 - 1986
- University of Michigan Medical SchoolClass of 1983
Certifications & Licensure
- CA State Medical License 1984 - 2026
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
- Fenretinide in Treating Children With Solid Tumors Start of enrollment: 1998 Mar 01
- Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma Start of enrollment: 2003 May 01
- N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma Start of enrollment: 2005 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- 1375 citationsTreatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic AcidKatherine K. Matthay, Judith G. Villablanca, Seeger Rc, Daniel O. Stram, Richard E. Harris
The New England Journal of Medicine. 1999-10-14 - 75 citationsPhase II Study of Oral Capsular 4-Hydroxyphenylretinamide (4-HPR/Fenretinide) in Pediatric Patients with Refractory or Recurrent Neuroblastoma: A Report from the Child...Judith G. Villablanca, Wendy B. London, Arlene Naranjo, Patrick McGrady, Matthew M. Ames
Clinical Cancer Research. 2011-11-01 - 54 citationsComparison of Iodine-123 Metaiodobenzylguanidine (MIBG) Scan and [18F]Fluorodeoxyglucose Positron Emission Tomography to Evaluate Response After Iodine-131 MIBG Therap...Denah R. Taggart, Myo M. Han, Alekist Quach, Susan Groshen, Wei Ye
Journal of Clinical Oncology. 2009-11-10